: We are submitting a proposal for a K24 Mid-Career Development Award to support the efforts of John N. van den Anker, M.D., Ph.D. Dr. van den Anker is a Board Certified Pediatrician who is also certified in Clinical Pharmacology; he is one of only 19 pediatricians world-wide who has this dual certification and is the only Neonatologist among them. Dr. van den Anker moved to Children's National Medical Center (CNMC) in 2002 to become Director of Pediatric Clinical Pharmacology, and Professor of Pediatrics and Pharmacology at the George Washington University School of Medicine and Health Sciences (GW). Significant institutional and departmental commitments, including financial support as documented in this application have been provided to build a premier academic pediatric clinical pharmacology research program. Dr. van den Anker is currently the P.I. of a number of external grants in support of his pharmacological research. His expertise is in the area of developmental changes in pharmacokinetics and pharmacodynamics of frequently used medicines in neonates. Dr. van den Anker has published over 100 peer-reviewed articles in the field of developmental and neonatal pharmacology, primarily focusing on the effect of renal function on clinical pharmacokinetics of frequently used medicines in the newborn. Until now Dr. van den Anker has been using traditional pharmacokinetic study design and analysis in his research. Despite his research productivity, there are recent advances in the methodology for studying pharmacokinetics, pharmacodynamics and pharmacogenetics that he needs to learn. The K24 award would offer him the opportunity for gaining skills in the new fields of population pharmacokinetics and pharmacogenomics and to mentor junior faculty in pediatric pharmacology research. In this proposal, he plan to mentor 4 junior pediatric faculty members who are conducting pharmacological studies in the areas of hematology, infectious diseases, anesthesiology and psychiatry. In addition, he will perform a research project that will focus on the development of a pharmacokinetic/pharmacodynamic (PK/PD) model for morphine dosing in preterm infants that will incorporate developmental changes (UGT2B7 activity and renal function) and pharmacogenetic information (UGT2B7 gene, COMT- and the (-opioid receptor gene) relevant to morphine pharmacokinetics and pharmacodynamics. The long-term goal of the proposed investigation is to improve the use of morphine in critically ill premature neonates. ? ?

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
1K24RR019729-01
Application #
6761579
Study Section
Pharmacology A Study Section (PHRA)
Program Officer
Wilde, David B
Project Start
2004-07-01
Project End
2009-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
1
Fiscal Year
2004
Total Cost
$141,423
Indirect Cost
Name
Children's Research Institute
Department
Type
DUNS #
143983562
City
Washington
State
DC
Country
United States
Zip Code
20010
Smits, Anne; van den Anker, John N; Allegaert, Karel (2017) Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use. J Pharm Pharmacol 69:350-360
Allegaert, Karel; van den Anker, John N (2014) Neonatal abstinence syndrome: on the evidence to add breastfeeding to any clinical pathway. Pediatr Crit Care Med 15:579-80
Rakhmanina, Natella Y; Neely, Michael N; Van Schaik, Ron H N et al. (2011) CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit 33:417-24
Darbari, Deepika S; Neely, Michael; van den Anker, John et al. (2011) Increased clearance of morphine in sickle cell disease: implications for pain management. J Pain 12:531-8
Rakhmanina, Natella Y; van den Anker, John N; Soldin, Steven J et al. (2010) Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit 32:273-81
Rakhmanina, Natella Y; van den Anker, John N (2010) Treating an HIV-infected paediatric patient: an easy task? Antivir Ther 15:293-6
Allegaert, Karel; Vanhaesebrouck, Sophie; Verbesselt, Rene et al. (2009) In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit 31:411-5
Knibbe, Catherijne A J; Krekels, Elke H J; van den Anker, Johannes N et al. (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 48:371-85
van den Anker, John N; Allegaert, Karel (2009) Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress? Eur J Clin Pharmacol 65:1159-60
Allegaert, K; van den Anker, J N; de Hoon, J N et al. (2008) Covariates of tramadol disposition in the first months of life. Br J Anaesth 100:525-32

Showing the most recent 10 out of 15 publications